The GRM8 antibody is a crucial tool in neuroscience research, targeting the metabotropic glutamate receptor 8 (mGluR8), a class C G-protein-coupled receptor (GPCR) primarily expressed in the central nervous system. mGluR8 is part of the group III metabotropic glutamate receptors, which inhibit neurotransmitter release by modulating cAMP signaling and ion channel activity. It plays a key role in regulating synaptic transmission, plasticity, and behaviors related to anxiety, cognition, and addiction. The GRM8 antibody is typically developed against specific epitopes, such as extracellular or intracellular domains, to detect receptor expression, localization, and post-translational modifications. It is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study GRM8 distribution in brain regions like the hippocampus, cortex, and cerebellum. Dysregulation of GRM8 has been implicated in neurological and psychiatric disorders, including schizophrenia, autism spectrum disorders, and epilepsy. Researchers also utilize this antibody to explore GRM8's interactions with ligands or downstream effectors, aiding drug development for neurological conditions. Both polyclonal and monoclonal variants are available, with validation often performed in knockout models to ensure specificity.